Influence of aspirin use on clinical outcomes of patients with hepatocellular carcinoma: a meta-analysis

Li, Xiaofei; Yu, Yuexiao; Liu, Liwen

doi:10.1016/j.clinre.2020.09.006

Cited by 9 publications

(9 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, the systematic review and meta-analysis by Tan et al [ 216 ] showed that aspirin use was associated with improved liver-related mortality (OR: 0.32, 95%CI: 0.15-0.70) and reduced risk of HCC recurrence (HR: 0.80, 95%CI: 0.75-0.86). The same was observed in the meta-analysis by Li et al [ 220 ], which demonstrated a reduced risk of HCC recurrence (RR: 0.74, 95%CI: 0.59-0.93; P = 0.01) and all-cause mortality (RR: 0.59, 95%CI: 0.47-0.73; P < 0.001). Although the evidence points toward a potential benefit of aspirin use in prevention of HCC, further prospective data is still necessary in the NAFLD/NASH population.…”

Section: Interventions To Prevent Nafld/nash-associated Hccsupporting

confidence: 81%

“…Also, an inverse relationship seems to exist between aspirin dose/duration of use and HCC risk, but this should be further confirmed[ 215 , 219 ]. There was no evidence of higher risk of bleeding with aspirin use, including in patients with HCC in most meta-analyses except one[ 216 - 220 ]. Moreover, the systematic review and meta-analysis by Tan et al [ 216 ] showed that aspirin use was associated with improved liver-related mortality (OR: 0.32, 95%CI: 0.15-0.70) and reduced risk of HCC recurrence (HR: 0.80, 95%CI: 0.75-0.86).…”

Section: Interventions To Prevent Nafld/nash-associated Hccmentioning

confidence: 99%

See 1 more Smart Citation

Screening and interventions to prevent nonalcoholic fatty liver disease/nonalcoholic steatohepatitis-associated hepatocellular carcinoma

Onişor¹

2023

World J Gastroenterol

View full text Add to dashboard Cite

Liver cancer is the sixth most commonly diagnosed cancer worldwide, with hepatocellular carcinoma (HCC) comprising most cases. Besides hepatitis B and C viral infections, heavy alcohol use, and nonalcoholic steatohepatitis (NASH)-associated advanced fibrosis/cirrhosis, several other risk factors for HCC have been identified ( i.e. old age, obesity, insulin resistance, type 2 diabetes). These might in fact partially explain the occurrence of HCC in non-cirrhotic patients without viral infection. HCC surveillance through effective screening programs is still an unmet need for many nonalcoholic fatty liver disease (NAFLD) patients, and identification of pre-cirrhotic individuals who progress to HCC represents a substantial challenge in clinical practice at the moment. Patients with NASH-cirrhosis should undergo systematic HCC surveillance, while this might be considered in patients with advanced fibrosis based on individual risk assessment. In this context, interventions that potentially prevent NAFLD/ NASH-associated HCC are needed. This paper provided an overview of evidence related to lifestyle changes ( i.e. weight loss, physical exercise, adherence to healthy dietary patterns, intake of certain dietary components, etc. ) and pharmacological interventions that might play a protective role by targeting the underlying causative factors and pathogenetic mechanisms. However, well-designed prospective studies specifically dedicated to NAFLD/NASH patients are still needed to clarify the relationship with HCC risk.

show abstract

Section: Interventions To Prevent Nafld/nash-associated Hccsupporting

confidence: 81%

Section: Interventions To Prevent Nafld/nash-associated Hccmentioning

confidence: 99%

Screening and interventions to prevent nonalcoholic fatty liver disease/nonalcoholic steatohepatitis-associated hepatocellular carcinoma

Onişor¹

2023

World J Gastroenterol

View full text Add to dashboard Cite

show abstract

“…41 From the bench to the bedside, several studies conducted on humans align with the hypothesis that a higher number of platelets may be associated with worse outcomes in patients with HCC and that APT may demonstrate a protective effect. [42][43][44][45] The present meta-analysis, which included 20 studies assessing the role of APT in HCC incidence and outcome following treatment, showed that patients treated with F I G U R E 2 Forest plot and meta-analysis showing the positive correlation between the use of APT and the reduced risk of HCC incidence. APT, anti-platelet therapy; HCC, hepatocellular carcinoma F I G U R E 3 Forest plot and meta-analysis showing the positive correlation between the use of APT and the reduced risk of overall death after any HCC treatment.…”

Section: Discussionmentioning

confidence: 64%

“…From the bench to the bedside, several studies conducted on humans align with the hypothesis that a higher number of platelets may be associated with worse outcomes in patients with HCC and that APT may demonstrate a protective effect. 42 , 43 , 44 , 45 …”

Section: Discussionmentioning

confidence: 99%

The role of antiplatelet therapies on incidence and mortality of hepatocellular carcinoma

Lai

Matthaeis

Finotti

et al. 2022

Eur J Clin Investigation

View full text Add to dashboard Cite

Aim To evaluate the impact of antiplatelet therapy (APT)on the incidence of hepatocellular carcinoma (HCC) and mortality following its treatment. Methods A systematic literature search was performed using PubMed and Cochrane Central Register of Controlled Trials Databases. Two HCC clinical settings were explored: (i) incidence, and (ii) death after any HCC treatment. Odds ratios (OR) and 95% confidence intervals (95%CI) were calculated to compare the pooled data between patients who received or did not receive APT. Results A total of 20 studies were identified, of whom 15 focused on HCC incidence, including 2,685,009 patients, and five on post‐treatment death, including 3281 patients. APT was associated with an overall reduced risk of HCC incidence (OR: 0.63; 95%CI = 0.51–0.79; p < 0.001) as well as of post‐treatment mortality (OR: 0.54; 95%CI = 0.35–0.83; p = 0.006). Conclusions Current data suggest that APT correlated with higher HCC incidence and poor overall survival following tumour treatment.

show abstract

“…It was observed that the recurrence of HCC was lower, and all-cause mortality was significantly reduced in patients who used aspirin ( P < 0.001). It was concluded that the utilization of aspirin is not linked to the risk of significant hemorrhage [15].…”

Section: Discussionmentioning

confidence: 99%

Effect of aspirin use on survival in patients with hepatocellular carcinoma

Aktan,

Ozdemir,

Karaoğullarindan

2023

European Journal of Gastroenterology &Amp; Hepatology

View full text Add to dashboard Cite

Background Hepatocellular carcinoma (HCC) is the seventh most prevalent cancer globally and is the third leading cause of cancer-related mortality. Aim The aim of this study was to evaluate the effect of aspirin use on the survival rates of individuals diagnosed with HCC. Methods The patients were divided into two groups: those who used aspirin and those who did not. Aspirin use was defined as individuals who had used aspirin either before or after the diagnosis of HCC. Aspirin usage was determined based on prescription records. The criteria for aspirin use were defined as a minimum of 3 months and a minimum daily dose of 100 mg. Survival time; The time elapsed after the diagnosis of HCC was calculated as ‘months’ Result Of the 300 cohorts studied in our study, 104 (34.6%) were using aspirin, while 196 (65.4%) were not. It was observed that bleeding occurred only in the patient group taking aspirin (P = 0.002). When evaluated in terms of survival time, it was observed that it was significantly higher in the patient group using aspirin (P = 0.001). Aspirin use was identified as factors that significantly impact survival (P < 0.05). Aspirin use was identified as independent risk factors that significantly impact of survival (P < 0.05). Conclusion The aspirin group had a similar metabolic and liver reserve as the other group and had a longer survival despite being older and more comorbid diseases.

show abstract

Influence of aspirin use on clinical outcomes of patients with hepatocellular carcinoma: a meta-analysis

Cited by 9 publications

References 35 publications

Screening and interventions to prevent nonalcoholic fatty liver disease/nonalcoholic steatohepatitis-associated hepatocellular carcinoma

Screening and interventions to prevent nonalcoholic fatty liver disease/nonalcoholic steatohepatitis-associated hepatocellular carcinoma

The role of antiplatelet therapies on incidence and mortality of hepatocellular carcinoma

Effect of aspirin use on survival in patients with hepatocellular carcinoma

Contact Info

Product

Resources

About